Esperion announces FDA approval of Nexletol
ANN ARBOR, Mich. — Esperion announced that the U.S. Food and Drug Administration (FDA) has approved Nexletol (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering medicine. Nexletol is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular
